Glycation lowers ApoA1 stability, destroys HDL in T2DM
ACCELERATE substudy shows no benefit of evacetrapib in patients with diabetes
Once-promising HDL-targeted therapy fails to show plaque regression
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy